3 documents found, page 1 of 1
Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced...
Vilhais, Guilherme; Alpuim Costa, Diogo; Fontes-Sousa, Mário; Ribeiro, Pedro Casal; Martinho, Filipa; Botelho de Sousa, CarolinaLocally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on thi...
The roadmap of RANKL/RANK pathway in cancer
Casimiro, Sandra; Vilhais, Guilherme; Fernandes Gomes, Inês; Costa, LuisThe receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and i...
Expression of receptor activator of NFkB (RANK) drives stemness and resistance ...
Fernandes Gomes, Inês; Almeida, Bernardo P. De; Dâmaso, Sara; Mansinho, André; Correia, Inês; Henriques, Sara; Duarte, Raquel; Vilhais, GuilhermeThe role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the express...